Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions: analysis in surgical and follow up series

M Sugiyama, Y Atomi, T Yamato

Abstract

Background—Differential diagnosis is often difficult for small (<20 mm) polypoid lesions of the gall bladder.

Aim—To assess the diagnostic accuracy of endoscopic ultrasonography (EUS) for polypoid lesions in a surgical and follow up series.

Methods—A total of 194 patients with small polypoid lesions underwent both ultrasonography and EUS. A tiny echogenic spot or an aggregation of echogenic spots and multiple microcysts or a comet tail artefact indicated cholesterol polyp and adenomyomatosis respectively. Other lesions were diagnosed as neoplastic (adenoma or adenocarcinoma). In the 58 patients who underwent surgery, the histological diagnoses were cholesterol polyp (n = 36), adenomyomatosis (n = 7), adenoma (n = 4), and adenocarcinoma (n = 11). Of the remaining 136 patients with an EUS diagnosis of non-neoplastic lesions, 125 were followed up with ultrasonography alone or with EUS for 1–8.7 years (mean 2.6 years).

Results—In the surgical series, EUS (97%) differentiated polypoid lesions more precisely than ultrasonography (76%). During follow up, the lesions remained unchanged in size in 109 (87%) of the 125 patients with non-neoplastic lesions diagnosed by EUS. No neoplastic lesions developed in these patients. Ultrasonography had shown lesions to be neoplastic in 13% of the follow up series.

Conclusions—EUS is highly accurate for differentially diagnosing polypoid gall bladder lesions. It is recommended when ultrasonography cannot rule out neoplastic lesions. Non-neoplastic lesions diagnosed by EUS may be followed and observed with ultrasonography.

(Gut 2000;46:250–254)

Keywords: gall bladder; polypoid lesion; cholesterol polyp; ultrasonography; endoscopic ultrasonography

The advent of ultrasonography has increased detection of polypoid gall bladder lesions, which are found in 5.6–6.9% of healthy subjects. However, differential diagnosis by means of imaging modalities is often difficult for polypoid lesions, particularly small (<20 mm in diameter) ones. These small polypoid lesions can be classified into non-neoplastic (cholesterol polyp and adenomyomatosis) and neoplastic (adenoma and adenocarcinoma). Cholesterol polyps are the most common type of polypoid lesion and have no malignant potential. Typically, on ultrasonography, cholesterol polyps are small (<10 mm) echogenic pedunculated masses without acoustic shadowing. However, some cholesterol polyps, particularly those larger than 10 mm, appear partially or completely echopenic on ultrasonography. Such polyps are difficult to distinguish from adenocarcinomas. Adenocarcinomas are uncommon but should be precisely differentiated from non-neoplastic lesions because some small polypoid carcinomas can be curatively resected. Therefore an imaging modality that allows accurate differential diagnosis is required.

We previously reported the high accuracy of endoscopic ultrasonography (EUS) in differentiating polypoid gall bladder lesions in a surgical series. In principle, non-neoplastic lesions prospectively diagnosed by EUS have been followed up instead of being excised in our department. Herein, the diagnostic accuracy of EUS for polypoid gall bladder lesions is assessed in a follow up series as well as a surgical series.

Patients and methods

Between 1988 and 1997, 194 consecutive patients underwent EUS for small (<20 mm in maximum diameter) polypoid lesions of the gall bladder which had been detected by transabdominal ultrasonography (89 men and 105 women with a mean age of 52 (range 22–81) years). Of the 194 patients, 131 were referred for further evaluation with EUS from other institutions, mainly because the doctors could not rule out neoplastic lesions on ultrasonography. In the 63 remaining patients, the polypoid lesions were first detected by ultrasonography in our department. In principle, EUS was indicated for polypoid lesions exceeding 5 mm or those suspected of neoplasia. Forty eight patients were symptomatic. In most of the other patients, the lesions were detected incidentally by ultrasonography during a regular health check or preoperative screening for other diseases. The interval between ultrasonography and EUS ranged from 0 to 25 days (mean 10 days). The maximum diameter of the polypoid lesions was determined ultrasonographically. In patients with multiple polyps, the size of the largest polyp was measured.

Abbreviation used in this paper: EUS, endoscopic ultrasonography.
Transabdominal ultrasonography was performed using a real-time scanner with a 3.5 MHz linear array or curved array transducer (SAL-77A or SSA-270A; Toshiba, Tokyo, Japan; or SSD-650 or SSD-2000; Aloka, Tokyo, Japan). EUS was performed using an echoendoscope with a 7.5 MHz rotating transducer (GF-UM2/EU-M2, GF-UM3/EU-M3, or GF-UM200/EU-M30; Olympus, Tokyo, Japan). The gall bladder was visualised from the duodenum and the gastric antrum. A balloon filled with 5–15 ml water was used to provide acoustic coupling. For sedation, 5–10 mg diazepam was administered intravenously.

Data on ultrasonography and EUS were obtained from prospective official reports. EUS was performed by one of the authors who had knowledge of the ultrasonographic findings. The previously reported ultrasonographic and EUS criteria for differential diagnosis of polypoid lesions were as follows.9–10 (a) Cholesterol polyps show an internal echo pattern characterised as a tiny echogenic spot (entire lesion appearing as a single 1–5 mm spot that is homogeneously and highly echogenic) or an aggregation of multiple highly echogenic 1–3 mm spots with or without echopenic areas (fig 1). (b) Adenomyomatosis (localised type)3 is imaged as a sessile echogenic mass containing multiple microcysts (usually composed of 2–8 mm cysts) or a comet tail artefact (V-shaped reverberation ultrasound artefact)7 8 (fig 2). (c) In the absence of echogenic spots, multiple microcysts, or a comet tail artefact, these lesions are diagnosed as neoplastic (adenocarcinoma or adenoma) (figs 3 and 4). Sessile lesions suggest malignancy.

All patients with suspected neoplastic lesions on EUS underwent surgery. In principle, surgery was not indicated for patients with an EUS diagnosis of non-neoplastic lesions, except for symptomatic cases or those undergoing combined operation for other abdominal diseases. Non-surgical cases were followed up, once or twice a year, by ultrasonography alone or with EUS. In our surgical series, the ultrasonographic and EUS diagnosis was compared with the histopathological diagnosis. In the follow up cases, changes in sonographic findings were investigated. Changes in size exceeding 3 mm on ultrasonography were defined as enlarged or reduced.

Informed consent was obtained from all patients. Results were analysed by Fisher’s exact probability test or the Wilcoxon test where appropriate. Differences were considered significant when p<0.05.

Results

In all 194 patients, the gall bladder was adequately visualised at EUS. The sizes of the polypoid lesions measured ultrasonographically approximated (within 2 mm) those measured at EUS. The initial EUS diagnosis of
polypoid gall bladder lesions included cholesterol polyp (n = 158), adenomyomatosis (localised type) (n = 19), and neoplastic lesions (n = 17).

Surgical Series

Of the 194 patients, 58 underwent cholecystectomy within one month of the EUS examination. Histological examination of the polypoid lesions disclosed cholesterol polyps in 36, adenomyomatosis in seven, adenoma in four, and adenocarcinoma in 11 patients (table 1). The lesion sizes measured after cholecystectomy approximated (within 2 mm) those measured ultrasonographically. The prevalence of neoplastic lesions was 0% in 1–5 mm, 19% in 6–10 mm, 33% in 11–15 mm, and 55% in 16–20 mm lesions. Before surgery, EUS had shown the polypoid lesions to be cholesterol polyps (n = 34), adenomyomatosis (n = 7), or neoplastic lesions (n = 17) (table 1). EUS and ultrasoundography correctly distinguished among polypoid lesions in 56 (97%) and 44 (76%) of 58 patients respectively; the difference was significant (p<0.01). In 12 of 36 patients with histologically confirmed cholesterol polyps, ultrasonography depicted a homogeneously or heterogeneously echogenic or entirely echogenic mass without aggregation of echogenic spots, which led to misdiagnosis of neoplastic lesions. During the follow up period, there was no change in lesion size in 109 (87%) of the 125 patients (table 4). Nine patients (7%) showed an increase in lesion size; the maximal increase was 4 mm (n = 2; over 3.5 and 4.2 years respectively). No patients showed changes in the configuration or internal echo pattern of the polypoid lesions at either EUS or ultrasonography. In 109 patients in whom both initial ultrasonography and EUS had diagnosed polypoid lesions as non-neoplastic, follow up ultrasonography and EUS (n = 21) showed no findings suggesting neoplasia. In the 16 remaining patients in whom non-neoplastic lesions had been diagnosed by EUS alone, follow up ultrasonography showed no structural changes. Of the 16 patients, 13 also underwent the follow up EUS, which diagnosed the lesions as non-neoplastic. In all nine patients who showed an increase in lesion size, follow up EUS disproved neoplastic lesions. Three patients underwent cholecystectomy for polypoid lesions which had been diagnosed as cholesterol polyps based on the initial EUS, after a 2–5 year observation period. The surgical indications were based on symptoms (13 mm lesion in one patient) or an increase in size (from 7 to 11 mm over a 3.5 year period in one patient; from 11 to 14 mm over a 2.5 year period in another). The latter two patients

### Table 1: Histological diagnosis and size of polypoid gall bladder lesions in the surgical series

<table>
<thead>
<tr>
<th>Size (mm)</th>
<th>Cholesterol polyp</th>
<th>Adenomyomatosis</th>
<th>Adenoma</th>
<th>Adenocarcinoma</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–5</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
</tr>
<tr>
<td>6–10</td>
<td>15</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td>11–15</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>16–20</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>36</td>
<td>7</td>
<td>4</td>
<td>11</td>
<td>58</td>
</tr>
</tbody>
</table>

### Table 2: EUS and ultrasonographic diagnosis of polypoid gall bladder lesions in the surgical series

<table>
<thead>
<tr>
<th>Pathological diagnosis</th>
<th>Cholesterol polyp</th>
<th>Adenomyomatosis</th>
<th>Neoplastic lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUS diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol polyp</td>
<td>34</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Adenomyomatosis</td>
<td>0</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Neoplastic lesion</td>
<td>2</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>Ultrasonographic diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol polyp</td>
<td>24</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Adenomyomatosis</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Neoplastic lesion</td>
<td>12</td>
<td>2</td>
<td>15</td>
</tr>
</tbody>
</table>

### Table 3: Endoscopic ultrasonographic (EUS) and ultrasonographic diagnosis of polypoid gall bladder lesions in the follow up series

<table>
<thead>
<tr>
<th>Ultrasoundographic diagnosis</th>
<th>Cholesterol polyp</th>
<th>Adenomyomatosis</th>
<th>Neoplastic lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUS diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol polyp</td>
<td>100</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>Adenomyomatosis</td>
<td>0</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>Neoplastic lesion</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>9</td>
<td>16</td>
</tr>
</tbody>
</table>

### Table 4: Change in size of polypoid gall bladder lesion in the follow up series

<table>
<thead>
<tr>
<th>Initial size (mm)</th>
<th>Enlarged</th>
<th>Unchanged</th>
<th>Reduced</th>
<th>Disappeared</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–5</td>
<td>4</td>
<td>25</td>
<td>0</td>
<td>2</td>
<td>31</td>
</tr>
<tr>
<td>6–10</td>
<td>4</td>
<td>65</td>
<td>3</td>
<td>0</td>
<td>72</td>
</tr>
<tr>
<td>11–15</td>
<td>1</td>
<td>13</td>
<td>1</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>16–20</td>
<td>0</td>
<td>6</td>
<td>1</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>9</td>
<td>109</td>
<td>5</td>
<td>2</td>
<td>125</td>
</tr>
</tbody>
</table>

FOLLOW UP SERIES

Of the 194 patients, 136 with an EUS diagnosis of non-neoplastic lesion did not undergo cholecystectomy during the first year of follow up. Nine patients with abdominal discomfort refused surgical treatment. The other patients were asymptomatic. Of these 136 patients, three died from non-biliary diseases 1.5–3 years later and eight were lost to follow up. The 125 remaining patients were followed up by ultrasonography, once or twice a year, for 1–8.7 years (mean 2.6 years). These 125 patients constituted the follow up series. Of the 125 patients, 34 underwent follow up EUS, mainly for polypoid lesions which had been ≥10 mm on the initial examination or were enlarged during follow up.

The initial EUS had shown the polypoid lesions to be cholesterol polyps (n = 114) or adenomyomatosis (n = 11) in all 125 patients in the follow up series (table 3). In 16 (13%) of the 125 patients, ultrasonography had indicated neoplastic lesions for similar reasons to those in the surgical series. The polypoid lesions were single in 45 and multiple in 69 of the 114 patients with cholesterol polyps diagnosed by EUS. All 11 lesions diagnosed as adenomyomatosis were single. The initial size of the lesion exceeded 10 mm in 22 (18%) patients (table 4).
underwent follow up EUS three and two and a half years after the initial examination but showed no changes in the echo pattern of the polypoid lesions. Histological examination confirmed cholesterol polyp in all three patients.

Discussion
Among polypoid gall bladder lesions, a solitary lesion, a diameter greater than 10 mm, a sessile appearance, low echogenicity, and rapid growth on ultrasonography have been reported to suggest adenocarcinoma. However, these ultrasonographic findings alone cannot definitely distinguish adenocarcinoma from non-neoplastic lesions. Although colour Doppler ultrasonography, enhanced computed tomography, and dynamic magnetic resonance imaging may facilitate differentiation of polypoid lesions by analysis of their vascularity, the diagnostic accuracy of these modalities remains unsatisfactory.

We have previously reported that the echo pattern rather than the size of polypoid lesions is important in differential diagnosis. A tiny echogenic spot or an aggregation of echogenic spots and multiple microcysts or a comet tail artefact are pathognomonic for cholesterol polyp and adenomyomatosis respectively. Polypoid lesions without such findings indicate neoplasia. An echogenic spot represents a mass of foamy histiocytes containing cholesterol, and an echogenic area corresponds to proliferation of glandular epithelia. Multiple microcysts and a comet tail artefact represent proliferation of Rokitansky-Aschoff sinus and intramural calculi respectively. EUS displays the fine structure of polypoid lesions more accurately than ultrasonography because the former provides images of higher resolution. In the present surgical series, EUS differentiated polypoid lesions more precisely than ultrasonography.

In our previous studies, EUS failed to differentiate reliably between adenomas and adenocarcinomas. They showed only that, of these lesions, all the sessile ones were malignant. Adenomas are known to have a malignant potential (adenoma-carcinoma sequence). Because adenomas and adenocarcinomas both require surgical treatment, distinguishing between these lesions is not essential for their management.

In the present study, the natural history of polypoid gall bladder lesions in 125 patients in whom cholesterol polyp or adenomyomatosis had been diagnosed by EUS. During a mean follow up period of 2.6 years, all the lesions remained unchanged in ultrasonographic structure. Most (87%) of the lesions, even including those larger than 10 mm, retained their initial size. None of the patients developed gall bladder carcinoma. Two patients showed the largest (4 mm) increase in lesion size over about 4 years. Because the mean follow up period (2.6 years) was shorter than this, the longer follow up study may be required.

The results in the follow up series also confirmed the diagnostic accuracy of EUS as a means of differentiating polypoid lesions. In 13% of the follow up series, the initial EUS detected features characteristic of non-neoplastic lesions which the initial ultrasonography had failed to show. For diagnosing neoplastic lesions, EUS was more specific than ultrasonography, while EUS was as sensitive as ultrasonography. In this study, all patients underwent both ultrasonography and EUS. However, EUS may be unnecessary in patients in whom ultrasonography produces characteristic findings of cholesterol polyp or adenomyomatosis.

Moriguchi and colleagues reported the natural history of polypoid lesions (presumably benign) during a five year follow up period in 103 patients. In their study, lesion size did not change in 84% of patients, although one patient developed gall bladder carcinoma. Therefore accurate discrimination of non-neoplastic from neoplastic lesions is required before entry into a follow up series. EUS is valuable for managing such potentially malignant polypoid lesions.

Ultrasonographic follow up every six months has been advocated for benign lesions. Regular ultrasonographic surveillance appears to be safer even for non-neoplastic lesions that EUS has initially diagnosed. If subsequent ultrasonography discloses any changes in size or structure of the polypoid lesions, re-investigation with EUS should be expedited. Cases in which follow up EUS can rule out neoplastic lesions may be appropriate for further careful follow up. As none of the present patients with EUS diagnosis of non-neoplastic lesions developed neoplasia, long term ultrasonographic surveillance may be unnecessary for such patients. This is an important problem to be solved in future.

The present study supports the following principles for management of small polypoid lesions of the gall bladder. Ultrasonography is the preferable modality for screening and following up polypoid lesions. On ultrasonography, polyps smaller than 5 mm composed of a single tiny echogenic spot and those containing at least a partial aggregation of echogenic spots should be diagnosed as cholesterol polyps. Polypoid lesions in which multiple microcysts or a comet tail artefact are shown indicate adenomyomatosis. Other polypoid lesions should be further examined by EUS. When EUS does not produce such findings in polypoid lesions, neoplasia (adenoma or adenocarcinoma) should be suspected and the lesions should be treated surgically. On the other hand, asymptomatic cholesterol polyps and adenomyomatosis do not require surgery and may be followed up by ultrasonography at intervals of 6–12 months. Changes in size or structure of polypoid lesions on follow up ultrasonography should prompt re-investigation with EUS.


Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions: analysis in surgical and follow up series

M Sugiyama, Y Atomi and T Yamato

Gut 2000 46: 250-254
doi: 10.1136/gut.46.2.250

Updated information and services can be found at:
http://gut.bmj.com/content/46/2/250

These include:

References
This article cites 18 articles, 1 of which you can access for free at:
http://gut.bmj.com/content/46/2/250#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/